Every drug discovery program has its own challenges. Scientists at Reaction Biology have 20 years of experience in problem-solving and decision making. Via blogs, we like to share some of our experiences and insight into our assays with the drug discovery community to support your journey to a preclinical drug candidate.
Immuno-oncology (IO) therapies are revolutionizing cancer treatment, but their complex interactions with the tumor microenvironment pose a challenge in preclinical testing. Enter syngeneic models: how do they differ from traditional models, and how can they be harnessed for IO drug development? Dive into the blog for answers.
Antibody-drug conjugates (ADCs) are emerging as powerful tools in the treatment against cancer. While they hold immense promise for targeted therapy, challenges in efficacy and safety remain. This blog explores the potential and limitations of ADCs, examining their design, function, and ongoing research for a comprehensive understanding of this innovative approach to cancer treatment.
Kinases, the master regulators of cellular signaling pathways, are prime targets for drug discovery. But with so many assays available to measure their activity, how do you choose the right tool for your research? This blog delves into the diverse landscape of kinase assays, empowering you to select the most effective method for investigating your drug targets.
Modelling bladder cancer (BC) for preclinical drug development is notoriously challenging. Due to the route of administration of BC treatments, orthotopic modelling represent the go-to-option for physiological relevance. Here we review current resources for in vivo BC research and describe the characterization of the MB49_luc bioluminescent model.
Running cell-based assays in multiple ways provides an opportunity to view a kinase inhibitor in action from different angles. At Reaction Biology, we offer three assay formats for cell-based kinase screening. In this blog, we compare the assay formats to help you choose the assay that is right for your research project.
While biochemical assays will likely remain a critical entry point for novel molecules into the kinase inhibitor drug discovery pipeline, the field has collectively achieved a state of maturation that increasingly demands priority for cell-based assays right out of the gate.
The ability of several small molecule kinase inhibitors to modulate immune responses, as well as potentially block various stages in SARS-CoV-2 life cycle suggests they may have an important role in the emerging therapeutic arsenal. Vetting inhibitor performance across sufficiently diverse cell lines expressing SARS-CoV-2 relevant features will anticipate clinical success.
Without rock-solid biophysical predictors of binding affinity and kinetics, the road from molecular screening and simulation to cell-based assays and in vivo testing is virtually unnavigable. Fully characterizing your COVID-19 drug candidate with a proven SPR methodology is the fundament of the successful development of efficacious drugs.
